press release

May 2, 2024

− Achieved First Quarter 2024 Global Net Product Revenues of $365 Million, Representing 32% Year Over Year Growth Compared to Q1 2023, Including Continued Momentum from Total TTR Delivering 29% Year Over Year Growth – − Demonstrated Strong Progress with Zilebesiran Hypertension Program with Positive Results from KARDIA 2 Phase 2 Study and Initiation of KARDIA 3 Phase 2 Study – ...

press release

April 7, 2024

– Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent Study Cohorts at Month 3 – – A Single Dose of Zilebesiran Resulted in Clinically Significant Additive Reductions in Office Systolic Blood Pressure at Month 3 and in Time Adjusted Office Systolic Blood Pressure at Month 6 Across ...

news

April 2, 2024

2023 was a year marked by a strong financial performance, excellent commercial execution, and exciting advances in our pipeline and platform. Most importantly, we helped to transform the lives of more than 5,000 patients around the world with our medicines. I am so excited about Alnylam and the enormous promise we hold. We have come far in our quest to ...

press release

March 5, 2024

– Study Met the Primary Endpoint Demonstrating Clinically Significant Systolic Blood Pressure Reductions at Month 3 When Zilebesiran Was Added to a Diuretic, Calcium Channel Blocker or Angiotensin Receptor Blocker – – Zilebesiran Demonstrated an Encouraging Safety and Tolerability Profile When Added to Standard of Care Antihypertensives – – Study Results Support Potential for Biannual Dosing of Zilebesiran – – Full ...

press release

February 15, 2024

− Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022 – − Company Announces Updated Statistical Analysis Plan and Timing for HELIOS B Phase 3 Study of Vutrisiran – − Announces U.S. FDA Clearance to Initiate Multiple Dosing in ALN APP Phase 1 Study – ...

news

December 14, 2023

Alnylam was founded in 2002 by a group of distinguished life sciences leaders who believed in the vast potential of a newly discovered, natural process of silencing genes called RNA interference (RNAi). They assembled a talented team of researchers and encouraged them to harness the technology to treat disease by “following the science.” That charge from leadership became ingrained ...

press release

December 13, 2023

– Company Anticipates Investigational New Drug (IND) Applications for Nine or More Programs with Targets Expressed in the Liver, Central Nervous System, Adipose Tissue, and Muscle by End of 2025 – – Positive Initial Phase 1 Results with ALN TTRsc04 Demonstrate Rapid Knockdown with Mean Serum TTR Reduction up to 97% with Durability Supporting Potential for Annual Dosing and an Encouraging ...

capella

December 13, 2023

On December 13, 2023, we hosted a virtual R&D Day event showcasing Alnylam’s late stage clinical efforts, next wave programs, and platform advances. The event included presentations from Alnylam senior leaders as well as guest speakers. To view the webcast, click here To view the presentation, click here Speakers: Akshay Vaishnaw, M.D., Ph.D. – Chief Innovation Officer Dr. Akshay Vaishnaw ...

press release

December 6, 2023

CAMBRIDGE, Mass. (BUSINESS WIRE) Dec. 6, 2023 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on Wednesday, December 13, 2023 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after ...

webcast

December 5, 2023